Cargando…

Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant syndrome characterized by skin piloleiomyomas, uterine leiomyomas and papillary type 2 renal cancer caused by germline mutations in the fumarate hydratase (FH) gene. Previously, we proposed renal imaging for FH mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: van Spaendonck-Zwarts, Karin Y., Badeloe, Sadhanna, Oosting, Sjoukje F., Hovenga, Sjoerd, Semmelink, Harry J. F., van Moorselaar, R. Jeroen A., van Waesberghe, Jan Hein, Mensenkamp, Arjen R., Menko, Fred H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3297757/
https://www.ncbi.nlm.nih.gov/pubmed/22086304
http://dx.doi.org/10.1007/s10689-011-9491-5
Descripción
Sumario:Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant syndrome characterized by skin piloleiomyomas, uterine leiomyomas and papillary type 2 renal cancer caused by germline mutations in the fumarate hydratase (FH) gene. Previously, we proposed renal imaging for FH mutation carriers starting at the age of 20 years. However, recently an 18-year-old woman from a Dutch family with HLRCC presented with metastatic renal cancer. We describe the patient and family data, evaluate current evidence on renal cancer risk and surveillance in HLRCC and consider the advantages and disadvantages of starting surveillance for renal cancer in childhood. We also discuss the targeted therapies administered to our patient.